Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

129 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
BET bromodomain inhibition as a therapeutic strategy to target c-Myc.
Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, Kastritis E, Gilpatrick T, Paranal RM, Qi J, Chesi M, Schinzel AC, McKeown MR, Heffernan TP, Vakoc CR, Bergsagel PL, Ghobrial IM, Richardson PG, Young RA, Hahn WC, Anderson KC, Kung AL, Bradner JE, Mitsiades CS. Delmore JE, et al. Among authors: issa gc. Cell. 2011 Sep 16;146(6):904-17. doi: 10.1016/j.cell.2011.08.017. Epub 2011 Sep 1. Cell. 2011. PMID: 21889194 Free PMC article.
The outcomes of patients with chronic myeloid leukemia treated with third-line BCR::ABL1 tyrosine kinase inhibitors.
Jabbour EJ, Sasaki K, Haddad FG, Issa GC, Garcia-Manero G, Kadia TM, Jain N, Yilmaz M, DiNardo CD, Patel KP, Kanagal-Shamanna R, Champlin R, Khouri IF, Dellasala S, Pierce SA, Kantarjian H. Jabbour EJ, et al. Among authors: issa gc. Am J Hematol. 2023 Apr;98(4):658-665. doi: 10.1002/ajh.26852. Epub 2023 Jan 31. Am J Hematol. 2023. PMID: 36683287 Free article.
Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantation.
Short NJ, Ong F, Ravandi F, Nogueras-Gonzalez G, Kadia TM, Daver N, DiNardo CD, Konopleva M, Borthakur G, Oran B, Al-Atrash G, Mehta R, Jabbour EJ, Yilmaz M, Issa GC, Maiti A, Champlin RE, Kantarjian H, Shpall EJ, Popat U. Short NJ, et al. Among authors: issa gc. Blood Adv. 2023 Jul 25;7(14):3573-3581. doi: 10.1182/bloodadvances.2022009632. Blood Adv. 2023. PMID: 37104058 Free PMC article.
Biologic features and clinical outcomes in newly diagnosed myelodysplastic syndrome with KMT2A rearrangements.
Siddiqui M, Konoplev S, Issa G, Kantarjian H, Daver N, Ravandi F, Kadia T, Tang G, Wang SA, Thakral B, Medeiros LJ, Pozdnyakova O, Pierce S, Montalban-Bravo G, Chien K, Hammond D, Sasaki K, Garcia-Manero G, Hasserjian RP. Siddiqui M, et al. Am J Hematol. 2023 Apr;98(4):E91-E94. doi: 10.1002/ajh.26858. Epub 2023 Feb 1. Am J Hematol. 2023. PMID: 36661399 Free article. No abstract available.
Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial.
Jabbour E, Short NJ, Jain N, Huang X, Montalban-Bravo G, Banerjee P, Rezvani K, Jiang X, Kim KH, Kanagal-Shamanna R, Khoury JD, Patel K, Kadia TM, Daver N, Chien K, Alvarado Y, Garcia-Manero G, Issa GC, Haddad FG, Kwari M, Thankachan J, Delumpa R, Macaron W, Garris R, Konopleva M, Ravandi F, Kantarjian H. Jabbour E, et al. Among authors: issa gc. Lancet Haematol. 2023 Jan;10(1):e24-e34. doi: 10.1016/S2352-3026(22)00319-2. Epub 2022 Nov 16. Lancet Haematol. 2023. PMID: 36402146 Clinical Trial.
A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis.
Senapati J, Muftuoglu M, Ishizawa J, Abbas HA, Loghavi S, Borthakur G, Yilmaz M, Issa GC, Dara SI, Basyal M, Li L, Naqvi K, Pourebrahim R, Jabbour EJ, Kornblau SM, Short NJ, Pemmaraju N, Garcia-Manero G, Ravandi F, Khoury J, Daver N, Kantarjian HM, Andreeff M, DiNardo CD. Senapati J, et al. Among authors: issa gc. Blood Cancer J. 2023 Jun 29;13(1):101. doi: 10.1038/s41408-023-00871-1. Blood Cancer J. 2023. PMID: 37386016 Free PMC article. Clinical Trial.
Low-Dose Dasatinib (50 mg Daily) Frontline Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: 5-Year Follow-Up Results.
Gener-Ricos G, Haddad FG, Sasaki K, Issa GC, Skinner J, Masarova L, Borthakur G, Alvarado Y, Garcia-Manero G, Jabbour E, Kantarjian H. Gener-Ricos G, et al. Among authors: issa gc. Clin Lymphoma Myeloma Leuk. 2023 Oct;23(10):742-748. doi: 10.1016/j.clml.2023.05.009. Epub 2023 May 23. Clin Lymphoma Myeloma Leuk. 2023. PMID: 37308342
Key role of microRNAs in Waldenström's macroglobulinemia pathogenesis.
Sacco A, Maiso P, Azab A, Azab F, Zhang Y, Liu Y, Ngo HT, Morgan B, Quang P, Issa G, Ghobrial IM, Roccaro AM. Sacco A, et al. Clin Lymphoma Myeloma Leuk. 2011 Feb;11(1):109-11. doi: 10.3816/CLML.2011.n.022. Clin Lymphoma Myeloma Leuk. 2011. PMID: 21454206
129 results